Cogstate (ASX:CGS) Common Stock: A$60.22 Mil (As of Dec. 2025)


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.76
GF Value A$2.05
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate Common Stock?

Cogstate ASX:CGS -0.72% 77 Common Stock is A$60.22 Mil as of Dec. 2025. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.05 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cogstate's quarterly common stock declined from Dec. 2024 (A$59.62 Mil) to Jun. 2025 (A$58.00 Mil) but then increased from Jun. 2025 (A$58.00 Mil) to Dec. 2025 (A$60.22 Mil).

Cogstate's annual common stock increased from Jun. 2023 (A$54.11 Mil) to Jun. 2024 (A$55.08 Mil) and increased from Jun. 2024 (A$55.08 Mil) to Jun. 2025 (A$58.00 Mil).

Cogstate Common Stock Historical Data

* Premium members only.

The historical data trend for Cogstate's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate Common Stock Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.51 51.44 54.11 55.08 58.00

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.75 55.08 59.62 58.00 60.22
ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$60.22 Mil mean?
Cogstate (ASX:CGS) has a Common Stock of A$60.22 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Cogstate and its competitors.
Is Cogstate's Common Stock too high?
Cogstate's current Common Stock is A$60.22 Mil. Overall, Cogstate has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Common Stock compare to VEEV and BTSG?
Cogstate's Common Stock of A$60.22 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Healthcare Providers & Services company?
A good Common Stock depends on the Healthcare Providers & Services industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Cogstate and its competitors. Cogstate's current Common Stock is A$60.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.05, compared to a current price of A$2.76 — trading 34.6% above its estimated fair value. The current Common Stock is A$60.22 Mil. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Common Stock is A$60.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.76 is trading 34.6% above its estimated GF Value™ of A$2.05. GuruFocus considers Cogstate to be Significantly Overvalued.

Key valuation signals for ASX:CGS:

  • Common Stock: A$60.22 Mil
  • GF Value™: A$2.05 vs. price of A$2.76 (34.6% above fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.76
Price
A$2.05
GF Value